Evaluation of the Effects of a Novel Pharmacological Agent on Nerve Sensitivity in Healthy Volunteers with Hyperexcitability Nerve Disorder

The primary objective of this study is to evaluate the effects of a new drug on the **sensitivity** of the nerves in healthy volunteers. This is clinically relevant as it aims to address **hyperexcitability nerve disorder**, a condition characterized by increased nerve sensitivity, which can lead to various neurological symptoms. Understanding the drug's impact on nerve sensitivity could provide insights into potential therapeutic approaches for managing this disorder.

The clinical trial involves participants diagnosed with **hyperexcitability nerve disorder**. The study population includes both male and female subjects, with an age range of 18 to 65 years. The sponsor did not provide information regarding the total number of participants. The trial population was selected without targeting any vulnerable groups. Participants' general health status and lifestyle considerations such as diet, physical activity, or habits were not specified by the sponsor. Key inclusion or exclusion criteria were not detailed in the provided data.

The clinical trial is designed to evaluate the effects of a new drug on the sensitivity of the nerves in healthy volunteers, specifically targeting **hyperexcitability nerve disorder**. This study is a Phase 3 trial, which is typically conducted to confirm the effectiveness of a treatment, monitor side effects, and collect information that will allow the drug to be used safely. The trial is structured as a randomized, double-blind, controlled study, ensuring that neither the participants nor the researchers know who is receiving the treatment or placebo, thus minimizing bias and ensuring the reliability of the results. The estimated recruitment start date is September 13, 2024, with the trial expected to conclude by December 12, 2024.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve a comprehensive evaluation to ensure that participants meet the necessary health standards for inclusion in the trial. Following successful screening, participants will be randomly assigned to either the treatment or control group. Throughout the trial, there will be scheduled follow-up visits to monitor the participants' health, assess the drug's effects, and ensure adherence to the study protocol. These visits are crucial for collecting data on the primary and secondary endpoints of the study. The trial will culminate in an end-of-study visit, where final assessments will be conducted to gather comprehensive data on the drug's efficacy and safety.

The expected length of participant involvement will span the duration of the trial, from the initial screening to the end-of-study visit. However, certain conditions may lead to early termination from the study, such as adverse reactions to the drug, non-compliance with the study protocol, or withdrawal of consent by the participant. These measures are in place to ensure the safety and well-being of all participants while maintaining the integrity of the trial data.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In this study, there is no mention of any **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment. The absence of these details suggests that the focus is primarily on the experimental medication, although further clarification would be necessary to confirm this aspect of the trial design.

Due to the lack of specific information, it is not possible to provide additional relevant details about drug administration, dosing schedules, or participant compliance monitoring. The trial documentation does not include any data on the product's authorization status, pharmaceutical form, or the origin of the active substances involved in the study.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on September 13, 2024, with an estimated completion date of December 12, 2024. The efficacy of the investigational treatment will be evaluated using specific parameters, although these parameters are not detailed in the provided data. The trial will follow a structured methodology to ensure the accurate collection and analysis of efficacy data. The trial's design and execution will adhere to rigorous standards typical of Phase 3 studies, ensuring that the results are reliable and scientifically valid. The assessment of efficacy will be conducted at predetermined intervals throughout the trial duration, although specific timepoints and tools for measurement are not specified in the available information.